News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Andres Gomez: Learn about resource optimization in Low- and Middle-Income Countries with Héctor Vaquera
Collage of Andres Gomez and Héctor Vaquera
Dec 12, 2023, 18:30

Andres Gomez: Learn about resource optimization in Low- and Middle-Income Countries with Héctor Vaquera

Andres Gomez, Associate Professor at The Autonomous University of Nuevo León, shared a post on X/Twitter:

“40 mg of nivolumab is enough for treating Hodgkin Lymphoma, plus or minus chemotherapy. Learn about resource optimization in Low- and Middle-Income Countries with Héctor Vaquera.”

Image

Source: Andres Gomez/X

Andres Gomez Autonomous University of Nuevo León cancer chemotherapy Héctor Vaquera Hodgkin lymphoma nivolumab OncoDaily Oncology
Special Coverage
Blog
Feb 11, 2025, 03:46
Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Blog
Feb 10, 2025, 18:28
Narjust Florez: Thank you ASCO - never imagined this to happen when still in my 30s
Blog
Feb 10, 2025, 18:24
Stephanie Graff: Thank you, ASCO, for the beautiful award
Science
Feb 10, 2025, 18:20
Leela Morená: Xenotransplantation of a porcine kidney for end-stage kidney disease
Blog
Feb 10, 2025, 18:17
New 2025-2027 committee nominations are now open - IASLC
Blog
Feb 10, 2025, 18:10
Rasu Shrestha: Proud of what we, as a team across Advocate Health, have already accomplished
Blog
Feb 10, 2025, 17:17
Nelson Dusetti on personalized chemotherapy for pancreatic cancer at Jeudi du PSCC
Blog
Feb 10, 2025, 16:55
Did you know that some cancer treatments cause cardiotoxicity? - Oncogene Cancer Research
Blog
Feb 10, 2025, 16:49
AAMC Statement on Drastic Cuts to NIH-Funded Research
Science
Feb 10, 2025, 16:45
Patrick Hwu: The potential of personalized cancer vaccines as an effective adjuvant therapy in RCC
Insight
Feb 10, 2025, 16:08
Drew Moghanaki: A common-sense interpretation of clinical trial data
Blog
Feb 10, 2025, 15:56
Herbert Loong: Join us for the inaugural ESMO TAT Asia 2025 meeting